BACKGROUND AND AIMS: (1) To establish the prevalence of mild cognitive impairment (MCI) in newly diagnosed drug-naive patients with Parkinson's disease adopting recently proposed and more conservative preliminary research criteria. (2) To investigate the relation between cognitive performances, MCI and motor dysfunction. METHODS: 132 consecutive newly diagnosed drug-naive PD patients and 100 healthy controls (HCs) underwent a neuropsychological evaluation covering different cognitive domains. Moreover, on the basis of the Unified Parkinson's Disease Rating Scale II/III, different motor scores were calculated and patients were classified in motor subtypes. 11 patients were excluded from the analysis during clinical follow-up which was continued at least 3 years from the diagnosis; therefore, the final sample included 121 patients. RESULTS: MCI prevalence was higher in PD (14.8%) patients than in HCs (7.0%). PD patients reported lower cognitive performances than HCs in several cognitive domains; HCs also outperformed cognitively preserved PD patients in tasks of episodic verbal memory and in a screening task of executive functions. MCI-PD patients presented a more severe bradykinesia score than non-MCI PD patients and patients mainly characterised by tremor had better performances in some cognitive domains, and specific cognitive-motor relationships emerged. CONCLUSIONS: Although the adoption of more conservative diagnostic criteria identified a lower MCI prevalence, we found evidence that newly diagnosed drug-naive PD patients present a higher risk of MCI in comparison with HCs. Axial symptoms and bradykinesia represent risk factors for MCI in PD patients and a classification of PD patients that highlights the presence/absence of tremor, as proposed in this study, is probably better tailored for the early stages of PD than classifications proposed for more advanced PD stages.
BACKGROUND AND AIMS: (1) To establish the prevalence of mild cognitive impairment (MCI) in newly diagnosed drug-naive patients with Parkinson's disease adopting recently proposed and more conservative preliminary research criteria. (2) To investigate the relation between cognitive performances, MCI and motor dysfunction. METHODS: 132 consecutive newly diagnosed drug-naive PDpatients and 100 healthy controls (HCs) underwent a neuropsychological evaluation covering different cognitive domains. Moreover, on the basis of the Unified Parkinson's Disease Rating Scale II/III, different motor scores were calculated and patients were classified in motor subtypes. 11 patients were excluded from the analysis during clinical follow-up which was continued at least 3 years from the diagnosis; therefore, the final sample included 121 patients. RESULTS: MCI prevalence was higher in PD (14.8%) patients than in HCs (7.0%). PDpatients reported lower cognitive performances than HCs in several cognitive domains; HCs also outperformed cognitively preserved PDpatients in tasks of episodic verbal memory and in a screening task of executive functions. MCI-PDpatients presented a more severe bradykinesia score than non-MCI PDpatients and patients mainly characterised by tremor had better performances in some cognitive domains, and specific cognitive-motor relationships emerged. CONCLUSIONS: Although the adoption of more conservative diagnostic criteria identified a lower MCI prevalence, we found evidence that newly diagnosed drug-naive PDpatients present a higher risk of MCI in comparison with HCs. Axial symptoms and bradykinesia represent risk factors for MCI in PDpatients and a classification of PDpatients that highlights the presence/absence of tremor, as proposed in this study, is probably better tailored for the early stages of PD than classifications proposed for more advanced PD stages.
Authors: V E Kelly; C O Johnson; E L McGough; A Shumway-Cook; F B Horak; K A Chung; A J Espay; F J Revilla; J Devoto; C Wood-Siverio; S A Factor; B Cholerton; K L Edwards; A L Peterson; J F Quinn; T J Montine; C P Zabetian; J B Leverenz Journal: Parkinsonism Relat Disord Date: 2015-04-14 Impact factor: 4.891
Authors: Robert S Eisinger; Daniel Martinez-Ramirez; Adolfo Ramirez-Zamora; Christopher W Hess; Leonardo Almeida; Michael S Okun; Aysegul Gunduz Journal: Parkinsonism Relat Disord Date: 2019-05-19 Impact factor: 4.891
Authors: Connie Marras; Melissa J Armstrong; Christopher A Meaney; Susan Fox; Brandon Rothberg; William Reginold; David F Tang-Wai; David Gill; Paul J Eslinger; Cindy Zadikoff; Nancy Kennedy; Fred J Marshall; Mark Mapstone; Kelvin L Chou; Carol Persad; Irene Litvan; Benjamin T Mast; Adam T Gerstenecker; Sandra Weintraub; Sarah Duff-Canning Journal: Mov Disord Date: 2013-03-20 Impact factor: 10.338